Chronic kidney disease (CKD) continues to be a major challenge for health care systems globally. The disease is a direct contributor to morbidity and mortality, and a risk factor for cardiovascular disease, a leading cause of death globally. Recent studies indicated that CKD related deaths were among the largest rises of causes of death between 2010 and 2019 which could be attributed, in part, to the increased prevalence of CKD risk factors including obesity, hypertension and diabetes. Therefore, there is an unfulfilled need to identify sensitive and reliable biomarkers that can detect early stages of CKD, effectively monitor disease progression and monitor prognostic treatment effects.
For example, diabetic nephropathy, which is a kidney-related complication that affects around 40% of type 1 and type 2 diabetic patients and is regarded as one of the most common causes of end-stage renal disease (ESRD) worldwide, is currently diagnosed and staged based on elevations in albuminuria. There is a great controversy over albuminuria’s role as a surrogate end-point for the chronic kidney disease. In addition, other studies pointed out that micro-albuminuria is not a precise predictor of DN risk as it showed considerable daily variation as its levels can be influenced by other conditions including exercise, certain types of diets, infections and high blood pressure. In some other cases, diabetic patients developed kidney failure while showing albuminuria.
Another example is Autosomal dominant polycystic kidney disease (ADPKD), the most common renal hereditary disease affecting one in every 800-1000 individuals worldwide. Serum creatinine and cystatin C have been used routinely to evaluate renal functions but as their levels are only elevated at late stages of the PKD, eGFR does not represent a sensitive tool to monitor the disease progression. Therefore, there is an unfulfilled need to identify sensitive and reliable biomarkers that can detect early stages of CKD and can effectively monitor disease progression and monitor prognostic treatment effects. The availability of such markers will improve CKD management and reduce adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death.
This Research Topic thus welcomes submissions that focus on highlighting advances in CKD disease diagnosis, management and treatment.
Chronic kidney disease (CKD) continues to be a major challenge for health care systems globally. The disease is a direct contributor to morbidity and mortality, and a risk factor for cardiovascular disease, a leading cause of death globally. Recent studies indicated that CKD related deaths were among the largest rises of causes of death between 2010 and 2019 which could be attributed, in part, to the increased prevalence of CKD risk factors including obesity, hypertension and diabetes. Therefore, there is an unfulfilled need to identify sensitive and reliable biomarkers that can detect early stages of CKD, effectively monitor disease progression and monitor prognostic treatment effects.
For example, diabetic nephropathy, which is a kidney-related complication that affects around 40% of type 1 and type 2 diabetic patients and is regarded as one of the most common causes of end-stage renal disease (ESRD) worldwide, is currently diagnosed and staged based on elevations in albuminuria. There is a great controversy over albuminuria’s role as a surrogate end-point for the chronic kidney disease. In addition, other studies pointed out that micro-albuminuria is not a precise predictor of DN risk as it showed considerable daily variation as its levels can be influenced by other conditions including exercise, certain types of diets, infections and high blood pressure. In some other cases, diabetic patients developed kidney failure while showing albuminuria.
Another example is Autosomal dominant polycystic kidney disease (ADPKD), the most common renal hereditary disease affecting one in every 800-1000 individuals worldwide. Serum creatinine and cystatin C have been used routinely to evaluate renal functions but as their levels are only elevated at late stages of the PKD, eGFR does not represent a sensitive tool to monitor the disease progression. Therefore, there is an unfulfilled need to identify sensitive and reliable biomarkers that can detect early stages of CKD and can effectively monitor disease progression and monitor prognostic treatment effects. The availability of such markers will improve CKD management and reduce adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death.
This Research Topic thus welcomes submissions that focus on highlighting advances in CKD disease diagnosis, management and treatment.
